Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Familial colon cancer is a cluster of colon cancer within a family. Most cases of colon cancer occur sporadically in people with little to no family history of the condition. Approximately 3-5% of colon cancer is considered 'hereditary' and is thought to be caused by an inherited predisposition tocolon cancer that is passed down through a family in an autosomal dominant or autosomal recessive manner. In some of these families, the underlying genetic cause is not known; however, many of these cases are caused by changes (mutations) in the APC , MYH , MLH1 , MSH2 , MSH6 , PMS2 , EPCAM , PTEN , STK11 , SMAD4 , BMPR1A , NTHL1 , POLE , and POLD1 genes (which are associated with hereditary cancer syndromes). An additional 10-30% of people diagnosed with colon cancer have a significant family history of the condition but have no identifiable mutation in a gene known to cause a hereditary predisposition to colon cancer. These clusters of colon cancer are likely due to a combination of gene(s) and other shared factors such as environment and lifestyle. High-risk cancer screening and other preventative measures such as prophylactic surgeries are typically recommended in people who have an increased risk for colon cancer based on their personal and/or family histories.
Biomarker and diagnostic research for familial colorectal cancer has been reported in the published literature.
1 clinical trial registered. Interventions under study include other interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
197 publications have been identified in PubMed for familial colorectal cancer. Research spans Basic Science / Preclinical (32%), Review / Meta-Analysis (30%), and Epidemiology / Natural History (17%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 64 | 32% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 4:33 PM UTC
Genetic and Rare Diseases Info Center
Research summaries |
60 |
30% |
Disease patterns and progression | 33 | 17% |
Testing and diagnosis research | 17 | 9% |
Clinical study results | 9 | 5% |
Other research | 5 | 3% |
Patient case studies | 5 | 3% |
New treatment approaches | 4 | 2% |
Shi W (2026). [PMID: 41933803](https://pubmed.ncbi.nlm.nih.gov/41933803/). *J Control Release*. [Gene Therapy / Novel Therapeutics]
Tan S (2026). [PMID: 41265630](https://pubmed.ncbi.nlm.nih.gov/41265630/). *Cancer Lett*. [Basic Science / Preclinical]
Marwitz T (2026). [PMID: 42113415](https://pubmed.ncbi.nlm.nih.gov/42113415/). *Fam Cancer*. [Review / Meta-Analysis]
Zhang X (2026). [PMID: 41412526](https://pubmed.ncbi.nlm.nih.gov/41412526/). *Free Radic Biol Med*. [Epidemiology / Natural History]
Vermani L (2026). [PMID: 41898618](https://pubmed.ncbi.nlm.nih.gov/41898618/). *Int J Mol Sci*. [Basic Science / Preclinical]
Maria-Alexia P (2026). [PMID: 41771225](https://pubmed.ncbi.nlm.nih.gov/41771225/). *Cancer Genet*. [Review / Meta-Analysis]
Sanduleanu-Dascalescu S (2026). [PMID: 41733729](https://pubmed.ncbi.nlm.nih.gov/41733729/). *Fam Cancer*. [Review / Meta-Analysis]
Loughrey M (2026). [PMID: 41513545](https://pubmed.ncbi.nlm.nih.gov/41513545/). *Semin Oncol Nurs*. [Review / Meta-Analysis]
Maurya DK (2026). [PMID: 41551531](https://pubmed.ncbi.nlm.nih.gov/41551531/). *World J Gastroenterol*. [Other]
Breßer M (2026). [PMID: 41213597](https://pubmed.ncbi.nlm.nih.gov/41213597/). *Zentralbl Chir*. [Review / Meta-Analysis]